![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
ResBiotic’s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal’s Pulmonary Microbiome Lab at UAB with research and expertise from the university’s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development program.
Lead Product(s): Probiotic
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: N/A Product Type: Large molecule
Partner/Sponsor/Collaborator: Timberline Holdings
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 29, 2021